BCRX

AI Memo

BioCryst

As of 2026-10-18/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

ORLADEYO pediatric-launch conversion • 2026-12-31

Base target: $9 / p=50% prob

Biggest risk

Q2 total revenue included $55.7 million of navenibart licensing revenue, which should not be extrapolated as recurring product sales. Strong Pharvaris Phase 3 results sharpen the future HAE competition risk; RBC reportedly downgraded BCRX to Sector Perform and cut its target from $13 to $11 in September. BioCryst Q2 release RBC rating report

Invalidation

Break below $5 or thesis failure.

What would change my mind?

ORLADEYO remains a recurring commercial foundation: Q2 revenue was $158.2 million, and pediatric uptake could support the maintained $625 million–$645 million 2026 product outlook. Pipeline data offer additional, unproven upside. BioCryst Q2 release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-18

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Navenibart ALPHA-ORBIT readout
ORLADEYO remains a recurring commercial foundation: Q2 revenue was $158.2 million, and pediatric uptake could support the maintained $625 million–$645 million 2026 product outlook.
Pipeline data offer additional, unproven upside.

BearKey bullets

BCX17725's small Phase 1 patient segment may produce inconclusive or unfavorable data; the pivotal navenibart result is not expected until Q3 2027.
Licensing revenue boosted Q2 reported growth but is not equivalent to recurring ORLADEYO sales; R&D costs rose with ALPHA-ORBIT.
BioCryst Q2 release

WatchKey bullets

ORLADEYO pediatric-launch conversion

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $9 (p=50%)

Target spread vs base: +41% / -41%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $9 (p=50%)Bear Target: $5 (p=25%)

Commentary

The deterministic prior is positive, but competitive news and the reported RBC downgrade warrant a cautious monitoring view. The packet's adjusted-close anchor fell from $8.55 on October 9 in the prior baseline to $7.79 on October 16, an approximately 8.9% decline; the cause of that interval move was not verified. The October 15 item stored as an investor release is an Insider Monkey article, not an official earnings release. Social, options, short-interest and employee-sentiment figures were unavailable; the zero entries are missing-data placeholders, not observations.

As of 2026-10-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Navenibart ALPHA-ORBIT readout

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Analysis 2026-10-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
ORLADEYO pediatric-launch conversion
U.S. pediatric oral-pellet shipments began in August, with 47 prescriptions written year-to-date at the August update. Sustained paid uptake and progress toward unchanged 2026 ORLADEYO revenue guidance of $625 million–$645 million remain to be demonstrated. [#8-K-2026-08-05] SEC earnings exhibit
Prob 60.00% • Move 8.00% • Priced-in 50.00%
EVENT2026-12-31
BCX17725 early patient data
BioCryst expects year-end 2026 data from a Phase 1 Netherton syndrome study segment enrolling up to 12 patients for three months. The small, early-stage dataset carries substantial interpretation risk. [#8-K-2026-08-05] SEC earnings exhibit
Prob 60.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Navenibart ALPHA-ORBIT readout
2027-09-30
Enrollment is complete, and BioCryst targets Q3 2027 top-line results for every-three-month and every-six-month dosing. Clinical differentiation and eventual commercial positioning remain unproven. [#8-K-2026-08-05] SEC earnings exhibit
Prob 75% • Move 18% • Priced-in 30%

Risks

BCX17725's small Phase 1 patient segment may produce inconclusive or unfavorable data; the pivotal navenibart result is not expected until Q3 2027.
Licensing revenue boosted Q2 reported growth but is not equivalent to recurring ORLADEYO sales; R&D costs rose with ALPHA-ORBIT. BioCryst Q2 release
Pediatric prescriptions may not convert into sustained reimbursed treatment or offset competition.
Potential ORLADEYO switching or pricing pressure from emerging oral HAE prophylaxis; Pharvaris' Phase 3 result is not a head-to-head comparison.
The secured term loan and royalty financing obligation constrain a simple cash-versus-market-cap valuation comparison. BioCryst Q2 release

Peers

Symbol	Summary
TAK	HAE-treatment-market comparator through TAKHZYRO, including pediatric prophylaxis, but Takeda is too diversified to be a clean corporate valuation peer. Takeda release
PHVS	Direct oral HAE-development comparator. Pharvaris reported positive Phase 3 prophylaxis results in September 2026, creating prospective competition; its therapy has not been compared head-to-head with ORLADEYO. Pharvaris release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-18

Loading AI feed…

Symbol

Summary

TAK

HAE-treatment-market comparator through TAKHZYRO, including pediatric prophylaxis, but Takeda is too diversified to be a clean corporate valuation peer. Takeda release

PHVS

Direct oral HAE-development comparator. Pharvaris reported positive Phase 3 prophylaxis results in September 2026, creating prospective competition; its therapy has not been compared head-to-head with ORLADEYO. Pharvaris release